2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Neutropenia
1
Neoplasms
1
Hematologic Neoplasms
1
Fever
1
Febrile Neutropenia
1
Interventions
Cytarabine
905
Cyclophosphamide
899
fludarabine
525
venetoclax
489
fludarabine phosphate
468
Azacitidine
460
Rituximab
431
Methotrexate
419
Etoposide
320
Filgrastim
299
Busulfan
296
Dexamethasone
286
Vincristine
285
Daunorubicin
283
Peripheral Blood Stem Cell Transplantation
258
Whole-Body Irradiation
243
Mycophenolic Acid
232
Decitabine
230
Granulocyte Colony-Stimulating Factor
227
Tacrolimus
220
Imatinib Mesylate
211
Idarubicin
205
Melphalan
202
Cyclosporine
182
Doxorubicin
177
Radiotherapy
169
Prednisone
163
Dasatinib
163
Mitoxantrone
161
Lenalidomide
160
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cilastatin, Imipenem Drug Combination
×
Other hematologic neoplasm
×
Clear all
NCT02149329
2019-09-25
SHORT
Amsterdam UMC, location VUmc
Phase 4
Completed
276 enrolled